Oklo Inc. (NYSE: OKLO) saw its shares climb 14.8% on Friday, extending a weekly gain of 24.7%, as investors shrugged off a quarter that showed little progress toward commercial reactor revenue. The stock closed at $48.42, giving the company an implied equity value of roughly $9.0 billion. After subtracting $3.0 billion in cash and marketable securities, the market is assigning approximately $6.0 billion to Oklo's operations and future projects.
The rally comes despite a Q2 report that revealed revenue of just $1.2 million, primarily from acquired businesses rather than core reactor operations. Research and development expenses more than tripled to $39.5 million, while general and administrative costs doubled to $34.2 million. The operating loss widened to $73.2 million, up 161% year-over-year. However, interest and dividend income of $23.2 million—19 times the top line—offset nearly a third of that loss, helping narrow the net loss to $48.5 million.
Oklo's balance sheet remains a key pillar of its investment thesis. The company raised $1.85 billion through stock sales in the first half, increasing share count by 15.3% to 186.0 million by August 4. With $3.0 billion in liquidity, the firm has ample runway to fund its ambitious deployment schedule. Management guided to $120–$150 million in operating cash use and $400–$500 million in capital spending for 2026, implying liquidity covers 4.6–5.8 times annual spending.
The positive catalyst driving the stock was the announcement that Oklo's Aurora 'Groves' low-power isotope reactor achieved first criticality less than a year after groundbreaking, with substantial construction completed in 229 days. CEO Jacob DeWitte called the milestone 'incredible,' but cautioned that the reactor is not yet the full Aurora design. Commissioning at the Texas site is expected to take another year, with initial isotope revenue more likely from the Idaho laboratory in early 2027. The Aurora-INL project remains targeted for 2028, though total project cost remains undisclosed.
Investor enthusiasm stands in stark contrast to the company's financial reality. The $6 billion cash-adjusted valuation implies expectations of significant future revenue, but the quarter showed no inflection point. Revenue breakdown included $800,000 from engineering and consulting, $168,000 from fabrication, and $242,000 from other work—none from commercial reactor power sales.
Wall Street remains largely constructive, with H.C. Wainwright's Sameer Joshi reiterating a Buy rating and $90 price target, implying 85.9% upside. Barclays values Oklo at $76 under a model assuming twelve 75-megawatt plants annually by 2035, sustained through 2050. The consensus rating is Overweight with a median target of $81.50, suggesting 68.3% upside. Truist's Christopher Souther holds a more cautious Hold with a $55 target.
Peer comparisons offer context. NuScale Power (NYSE: SMR) is the closest listed reactor developer, while Centrus Energy (NYSEAMERICAN: LEU) serves as a potential fuel supplier. Oklo's letter of intent with Centrus could cover up to five Aurora units, with deliveries potentially starting in 2029, though a definitive agreement is still pending.
For investors, the key question is whether the current valuation justifies the execution risk. A move to $100 per share would imply $18.6 billion in equity value, or $15.6 billion after subtracting current liquidity—2.6 times Friday's cash-adjusted figure. That would require more than just another milestone; it would demand a credible path to commercial deployment and revenue generation.
In the near term, market watchers will focus on post-results analyst revisions and broader economic data. July consumer inflation arrives Wednesday, followed by producer prices Thursday. Interest rates matter doubly for Oklo: they influence the valuation of growth stocks and the returns on its $2.95 billion in interest-sensitive assets.
Risks remain significant, including potential delays in Aurora licensing or construction, higher first-of-a-kind costs, fuel supply constraints, and the nonbinding nature of customer commitments. While Oklo's cash cushion provides time, it does not guarantee successful execution. As the company moves from milestone to milestone, investors will need to weigh the promise of advanced nuclear technology against the substantial work still ahead.
